U-Neuron Biomedical Inc

As of June 30, 2026, U-Neuron Biomedical Inc carries a market capitalization of 1.32B, placing it among publicly traded companies globally. Its enterprise value stands at 742.33M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, U-Neuron Biomedical Inc has 39.80M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, U-Neuron Biomedical Inc maintains a current ratio of 10.40, meaning it holds 10.4x the short-term assets needed to cover near-term liabilities.

As of the close on October 22, 2026, U-Neuron Biomedical Inc's stock has gained approximately 35.76% over the past 52 weeks. The 50-day moving average sits at 51.24, while the 200-day moving average is 39.49.

As of June 30, 2026, U-Neuron Biomedical Inc holds 598.11M in cash and equivalents against 24.95M in total debt, resulting in a net debt position of -451.11M. Total book value stands at 678.57M, with working capital of 575.58M providing operational flexibility.

U-Neuron Biomedical Inc's most recent stock split took place on June 20, 2024 with a 711:758 split ratio.